|
KMID : 0670719980030010039
|
|
Journal of the Korean Society Hyperthermia Oncology
1998 Volume.3 No. 1 p.39 ~ p.46
|
|
|
Improved Local Control and Survival by Addition of Hyperthermia to Radiotherapy in Patients with Advanced Intrapelvic Tumours
|
|
J. van der Zee
D Gonzalez Gonzalez/G. C. van Rhoon/J. D. P.van Dijk/W.L.J. van Putten/A.A. M Hart/P.C.M. Koper
|
|
|
Abstract
|
|
|
|
Experimental research has shown that HT is an effective cell killing agent especially to cells in a hypoxic, nutrient deprived and low pH environment, which conditions are specifically found in malignant tumours. The combination of RT with HT should result in at least a complementary tumouricidal effect; besides, the combination provides supra-additive cytotoxic effects. The existing clinical data have confirmed the findings from experimental research. Recently, the therapeutic gain by HT in addition to RT has been proven by randomized comparative studies in various tumour types: lymph node metastasis from head and neck tumours, malignant melanoma, breast cancer and glioblastoma multiforme. In patients with inoperable tumours of the bladder, cervix or rectum, the chance to achieve local control with standard radiotherapy is relatively small. For these patient groups, a local failure in general means that the disease will be fatal. In the Netherlands, two prospective randomized trials started in 1990. In 1993, the Rotterdam group had to report results to the Dutch Health Insurance Council, which was financially supporting the Rotterdam trial. At that time only 79 patients had been included. In the Amsterdam trial, 68 patients were entered. In the combined studies, a significant higher CR rate was observed following combined treatment compared with radiotherapy alone. The numbers of patients were too low to demonstrate a survival benefit. It was decided to continue the studies and the cooperation. In 1996, the studies were close(1. The results of the analysis performed in January 1998 are presented here. The median follow-up time of all patients was 21 months; 16 months for rectal cancer (n=143), 29 months for cervix cancer. (n=115), an(1 24 months for bladder cancer (n=102).
|
|
|
KEYWORD
|
|
|
|
|
|
FullTexts / Linksout information
|
|
|
|
|
|
Listed journal information
|
|
|
|
|